Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

1,770

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

November 20, 2024

Study Completion Date

August 31, 2025

Conditions
Arthropathy of KneeAntibiotic Prophylaxis
Interventions
DRUG

Cefazolin

"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."

Trial Locations (14)

10003

NYU School of Medicine, New York

19107

Rothman Institute, Philadelphia

21204

University of Maryland St. Joseph Medical Center & Orthopedic Associates, Towson

22939

Augusta Health, Fishersville

27703

Duke University Medical Center, Durham

29208

University of South Carolina, Columbia

30322

Emory University, Atlanta

39216

University Of Mississippi Medical Center, Jackson

39759

Mississippi Bone and Joint Clinic, Starkville

43210

Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

76508

BaylorScott&White Research Institute, Temple

94143

University of California, San Francisco, San Francisco

08873

University Orthopaedic Associates, LLC, Somerset

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

American Association of Hip and Knee Surgeons

OTHER

collaborator

Orthopedic Research and Education Foundation

OTHER

lead

Duke University

OTHER

NCT03283878 - Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial | Biotech Hunter | Biotech Hunter